IP Library › Granted Patent US 10,221,393
Granted Patent B2
US 10,221,393 · App. 15/627,381 · Granted Mar 5, 2019

Methods of reprogramming cells

Inventors: Douglas A. Melton (Lexington, MA); Qiao Zhou (Lexington, MA)
Assignee: President and Fellows of Harvard College
C12N5/0676C12N2501/60C12N2799/022
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,221,393
App. No.
15/627,381
Granted
Mar 5, 2019
Kind
B2
Abstract

The present invention provides methods of reprogramming cells, for example, directly reprogramming a somatic cell of a first cell type into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for reprogramming a cell of an endoderm origin to a cell having pancreatic β-cell characteristics. The present invention also relates to an isolated population comprising reprogrammed cells, compositions and their use in the treatment of diabetes mellitus. In particular, the present invention relates to reprogramming a cell of an endoderm origin to a cell having pancreatic β-cell characteristics by increasing the protein expression of at least one transcription factor selected from Pdx1, Ngn3 or MafA in the cell of endoderm origin to reprogram the cell of an endoderm cell to a cell which exhibits at least one or at least two characteristics of an endogenous pancreatic β-cell.

Claims (5)

1. A method for the treatment of a subject with diabetes, the method comprising administering a composition comprising an isolated population of pancreatic β-like cells obtained from a population of mature exocrine cells by a process comprising increasing the protein expression of Pdx-1, Ngn3, and MafA, or a functional fragment thereof, in the mature exocrine cells, wherein the pancreatic β-like cells do not express pancreatic hormones other than insulin.

2. The method of claim 1 , wherein the pancreatic β-like cells are produced from mature exocrine cells obtained from the same subject as the composition is administered to.

3. The method of claim 1 , wherein the subject has, or has an increased risk of developing, diabetes.

4. The method of claim 1 , wherein the diabetes is selected from the group consisting of: Type I diabetes, Type II diabetes and pre-diabetes.

5. The method of claim 1 , wherein the subject has, or has an increased risk of developing, a metabolic disorder.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2019
From: MELTON, DOUGLAS
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 048202/0866 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2019
From: HOWARD HUGHES MEDICAL INSTITUTE
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 048202/0893 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2017
From: ZHOU, QIAO
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 042812/0582 →
Continuity (3)
Continuation 13060123
Provisional Application 61090936 · Aug 22, 2008
Related Publication 20170355962A1 · Dec 14, 2017
Cited By (1)
US 12,285,543